Harmony Biosciences Q3 2024 Adj. EPS $1.03 Beats $0.67 Estimate, Sales $186.038M Beat $184.056M Estimate
Portfolio Pulse from Benzinga Newsdesk
Harmony Biosciences reported its Q3 2024 financial results, with adjusted EPS of $1.03 surpassing the estimated $0.67, and sales of $186.038 million exceeding the expected $184.056 million.
October 29, 2024 | 11:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Harmony Biosciences' Q3 2024 earnings report shows a strong performance with EPS and sales both exceeding expectations.
The company's adjusted EPS of $1.03 significantly beat the estimate of $0.67, and sales of $186.038 million also surpassed expectations. This strong financial performance is likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100